EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

International Society of Urological Pathology ( ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial

David Dearnaley, Clare L Griffin iD, Pedro Silva, Anna Wilkins, Christine Stuttle, Isabel Syndikus, Shama Hassan, Julia Pugh, Clare Cruickshank, Emma Hall iD, Catherine M Corbishley

BJU International · 2024-02 · 133 (2) · 179-187

DOI: 10.1111/bju.16133 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJU International, online erschienen am 07.08.2023. Verfasst von David Dearnaley und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Institute of Cancer Research, London, UK. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare the results of Gleason Grade Group (GGG) classification following central pathology review with previous local pathology assessment, and to examine the difference between using overall and worst GGG in a large patient cohort treated with radiotherapy and short‐course hormone therapy. Patients and Methods Patients with low‐ to high‐risk localized prostate cancer were randomized into the multicentre CHHiP fractionation trial between 2002 and 2011. Patients received short‐course hormone therapy (≤6 month) and radical intensity‐modulated radiotherapy (IMRT). Of 2749 consented patients, 1875 had adequate diagnostic biopsy tissue for blinded central pathology review. The median follow‐up was 9.3 years. Agreement between local pathology and central pathology‐derived GGG and between central pathology‐derived overall and worst GGG was assessed using kappa (κ) statistics. Multivariate Cox regression and Kaplan–Meier methods were used to compare the biochemical/clinical failure (BCF) and distant metastases (DM) outcomes of patients with GGG 1–5.

Results

There was poor agreement between local pathology‐ and central pathology‐derived GGG (κ = 0.19) but good agreement between overall and worst GGG on central pathology review (κ = 0.89). Central pathology‐derived GGG stratified BCF and DM outcomes better than local pathology, while overall and worst GGG on central pathology review performed similarly. GGG 3 segregated with GGG 4 for BCF, with BCF‐free rates of 90%, 82%, 74%, 71% and 58% for GGGs 1–5, respectively, at 8 years when assessed using overall GGG. There was a progressive decrease in DM‐free rates from 98%, 96%, 92%, 88% and 83% for GGGs 1–5, respectively, at 8 years with overall GGG. Patients ( n = 57) who were upgraded from GGG 2–3 using worst GS had BCF‐free and DM‐free rates of 74% and 92% at 8 years. CHHiP eligibility criteria limit the interpretation of these results.

Conclusion

Contemporary review of International Society of Urological Pathology GGG successfully stratified patients treated with short‐course hormone therapy and IMRT with regard to both BCF‐free and DM‐free outcomes. Patients upgraded from GGG 2 to GGG 3 using worst biopsy GS segregate with GGG 3 on long‐term follow‐up. We recommend that both overall and worst GS be used to derive GGG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstateProstatic NeoplasmsMaleHumansProstatectomyNeoplasm GradingHormones

Stichwörter der Autor:innen

Gleason scoreISUP Grade Groupcarcinomaclinical trialprostateradiotherapy

Substanzen

Hormones

Autor:innen und Institutionen

  • The Institute of Cancer Research, London, UK.
  • Royal Marsden Hospital NHS Foundation Trust, Sutton, UK.
  • Clinical Trials and Statistics Unit at the Institute of Cancer Research, London, UK.
  • Clatterbridge Cancer Centre, Bebington, UK.

ORCID-Profile: Clare L Griffin, Emma Hall

Förderung

  • Cancer Research UK

Zitieren

APA

Dearnaley, D., Griffin, C. L., Silva, P., Wilkins, A., Stuttle, C., Syndikus, I., Hassan, S., Pugh, J., Cruickshank, C., Hall, E., & Corbishley, C. M. (2024). International Society of Urological Pathology ( ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial. BJU International, 133(2), 179-187. https://doi.org/10.1111/bju.16133

Vancouver

Dearnaley D, Griffin CL, Silva P, Wilkins A, Stuttle C, Syndikus I, et al. International Society of Urological Pathology ( ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial. BJU International. 2024;133(2):179-187. doi:10.1111/bju.16133

BibTeX
@article{Dearnaley2024,
  author = {Dearnaley, David and Griffin, Clare L and Silva, Pedro and Wilkins, Anna and Stuttle, Christine and Syndikus, Isabel and Hassan, Shama and Pugh, Julia and Cruickshank, Clare and Hall, Emma and Corbishley, Catherine M},
  title = {International Society of Urological Pathology ( ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial},
  journal = {BJU International},
  year = {2024},
  volume = {133},
  number = {2},
  pages = {179--187},
  doi = {10.1111/bju.16133}
}
Kostenlos starten →